PTK2 and mesothelioma: Recently, phase I studies of FAK inhibitors (GSK2256098 and VS-6063) in patients with advanced solid tumors showed clinical activity in patients with mesothelioma, with one study suggesting particularly enhanced activity in patients with mesothelioma lacking merlin [91, 92].